UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics
URGN Price/Volume Stats
| Current price | $10.64 | 52-week high | $20.70 |
| Prev. close | $10.71 | 52-week low | $10.51 |
| Day low | $10.51 | Volume | 1,396,900 |
| Day high | $11.08 | Avg. volume | 492,703 |
| 50-day MA | $12.05 | Dividend yield | N/A |
| 200-day MA | $13.92 | Market Cap | 249.55M |
URGN Stock Price Chart Interactive Chart >
UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.
URGN Price Returns
| 1-mo | -7.88% |
| 3-mo | -21.42% |
| 6-mo | -39.10% |
| 1-year | -26.62% |
| 3-year | 17.83% |
| 5-year | -68.85% |
| YTD | -29.07% |
| 2023 | 69.11% |
| 2022 | -6.73% |
| 2021 | -47.23% |
| 2020 | -46.00% |
| 2019 | -22.50% |
Loading social stream, please wait...